Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study

Background: Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability. Methods: The eMERGE-III study (Electronic Medical Records and Genomics Phase III) is a multicenter prospective cohort that included 21 846 participants without previous indication for cardiac genetic testing. Participants were sequenced for 109 Mendelian disease genes, including 10 linked to arrhythmia syndromes. Variant carriers were assessed with electronic health record–derived phenotypes and follow-up clinical examination. Selected variants of uncertain significance (n=50) were characterized in vitro with automated electrophysiology experiments in HEK293 cells. Results: As previously reported, 3.0% of participants had P/LP variants in the 109 genes. Herein, we report 120 participants (0.6%) with P/LP arrhythmia variants. Compared with noncarriers, arrhythmia P/LP carriers had a significantly higher burden of arrhythmia phenotypes in their electronic health records. Fifty-four participants had variant results returned. Nineteen of these 54 participants had inherited arrhythmia syndrome diagnoses (primarily long-QT syndrome), and 12 of these 19 diagnoses were made only after variant results were returned (0.05%). After in vitro functional evaluation of 50 variants of uncertain significance, we reclassified 11 variants: 3 to likely benign and 8 to P/LP. Conclusions: Genome sequencing in a large population without indication for arrhythmia genetic testing identified phenotype-positive carriers of variants in congenital arrhythmia syndrome disease genes. As the genomes of large numbers of people are sequenced, the disease risk from rare variants in arrhythmia genes can be assessed by integrating genomic screening, electronic health record phenotypes, and in vitro functional studies. Registration: URL: https://www.clinicaltrials.gov; Unique identifier; NCT03394859.

[1]  W. Chung,et al.  ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) , 2021, Genetics in Medicine.

[2]  S. Priori,et al.  Cardiac ryanodine receptor calcium release deficiency syndrome , 2021, Science Translational Medicine.

[3]  R. Redon,et al.  SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families , 2020, Circulation. Genomic and precision medicine.

[4]  Dona M. Kanavy,et al.  Variant Classification Concordance using the ACMG-AMP Variant Interpretation Guidelines across Nine Genomic Implementation Research Studies. , 2020, American journal of human genetics.

[5]  R. Redon,et al.  Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls , 2020, Genetics in medicine : official journal of the American College of Medical Genetics.

[6]  Matthew S. Lebo,et al.  Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions , 2020, Nature Communications.

[7]  K. Musunuru,et al.  Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. , 2020, Circulation. Genomic and precision medicine.

[8]  The eMERGE Clinical Annotation Working Group.  Frequency of genomic secondary findings among 21,915 eMERGE network participants , 2020 .

[9]  Kenneth A. Matreyek,et al.  High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel KV11.1. , 2020, Heart rhythm.

[10]  M. Perez,et al.  An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome , 2020, Circulation.

[11]  M. Perez,et al.  An International Multicenter Evaluation of Type 5 Long QT Syndrome , 2020, Circulation.

[12]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[13]  G. Lukács,et al.  High-throughput phenotyping of heteromeric human ether-à-go-go-related gene potassium channel variants can discriminate pathogenic from rare benign variants. , 2020, Heart rhythm.

[14]  M. Khoury,et al.  DNA-Based Population Screening: Potential Suitability and Important Knowledge Gaps. , 2019, JAMA.

[15]  D. Roden,et al.  High-throughput reclassification of SCN5A variants , 2019, bioRxiv.

[16]  Kenneth A. Matreyek,et al.  An improved platform for functional assessment of large protein libraries in mammalian cells , 2019, Nucleic acids research.

[17]  Lorenzo L. Pesce,et al.  Pathogenic and Uncertain Genetic Variants Have Clinical Cardiac Correlates in Diverse Biobank Participants , 2019, bioRxiv.

[18]  D. Roden,et al.  Multiple mechanisms underlie increased cardiac late sodium current. , 2019, Heart rhythm.

[19]  Matthew S. Lebo,et al.  The eMERGE genotype set of 83,717 subjects imputed to ~40 million variants genome wide and association with the herpes zoster medical record phenotype , 2018, Genetic epidemiology.

[20]  Heidi L. Rehm,et al.  Harmonizing Clinical Sequencing And Interpretation For The Emerge III Network , 2018, bioRxiv.

[21]  S. Manley,et al.  Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.

[22]  J. Brugada,et al.  Present Status of Brugada Syndrome: JACC State-of-the-Art Review. , 2018, Journal of the American College of Cardiology.

[23]  D. Roden,et al.  SCN5A (NaV1.5) Variant Functional Perturbation and Clinical Presentation: Variants of a Certain Significance , 2018, Circulation. Genomic and precision medicine.

[24]  Risha Govind,et al.  CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation , 2018, Genetics in Medicine.

[25]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[26]  James M Ford,et al.  Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk , 2017, Genetics in Medicine.

[27]  W. Shimizu,et al.  Gene-Based Risk Stratification for Cardiac Disorders in LMNA Mutation Carriers , 2017, Circulation. Cardiovascular genetics.

[28]  Alfred L. George,et al.  High Throughput Functional Evaluation of KCNQ1 Decrypts Variants of Unknown Significance , 2017, bioRxiv.

[29]  Maitreya J. Dunham,et al.  Variant Interpretation: Functional Assays to the Rescue. , 2017, American journal of human genetics.

[30]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[31]  D. MacArthur,et al.  Using high-resolution variant frequencies to empower clinical genome interpretation , 2016, Genetics in Medicine.

[32]  A. Wilde,et al.  Catecholaminergic Polymorphic Ventricular Tachycardia. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[33]  Xiaowei Zhan,et al.  RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data , 2016, Bioinform..

[34]  Michael J Ackerman,et al.  Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records. , 2016, JAMA.

[35]  M. Ackerman,et al.  Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain/unknown significance issue. , 2015, Heart rhythm.

[36]  S. Priori,et al.  Genetics of sudden cardiac death. , 2015, Circulation research.

[37]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[38]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[39]  M. Ackerman,et al.  Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. , 2013, Translational research : the journal of laboratory and clinical medicine.

[40]  M. Rieder,et al.  Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. , 2012, American journal of human genetics.

[41]  Jorge Oliveira Santos,et al.  Criteria to predict carriers of a novel SCN5A mutation in a large Portuguese family affected by the Brugada syndrome. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[42]  A. Leenhardt,et al.  Catecholaminergic Polymorphic Ventricular Tachycardia , 2012, Circulation. Arrhythmia and electrophysiology.

[43]  Michael J Ackerman,et al.  Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. , 2011, Heart rhythm.

[44]  A. Wilde,et al.  SCN5A Mutations and the Role of Genetic Background in the Pathophysiology of Brugada Syndrome , 2009, Circulation: Cardiovascular Genetics.

[45]  S. Priori,et al.  High Efficacy of β-Blockers in Long-QT Syndrome Type 1: Contribution of Noncompliance and QT-Prolonging Drugs to the Occurrence of β-Blocker Treatment “Failures” , 2009, Circulation.

[46]  Dan M. Roden,et al.  Long-QT Syndrome , 2008 .

[47]  T. Rognum,et al.  Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers , 2008, Scandinavian journal of clinical and laboratory investigation.

[48]  J. Seidman,et al.  Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. , 1999, The New England journal of medicine.

[49]  S. Priori,et al.  Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.